Vol 95, No 4 (2024)
Research paper
Published online: 2023-10-12

open access

Page views 509
Article views/downloads 935
Get Citation

Connect on Social Media

Connect on Social Media

Меtformin-associated maternal and neonatal outcomes in women with gestational diabetes — a retrospective cohort study

Vesselina Evtimova Yanachkova1, Radiana Staynova2, Svetoslav Stoev3, Zdravko Kamenov4
Pubmed: 37842989
Ginekol Pol 2024;95(4):259-265.


Objectives: To assess the maternal and neonatal outcomes in women with GDM treated with metformin, medical nutrition therapy (MNT) or insulin.

Material and methods: The current retrospective cohort study includes data from 233 women diagnosed with GDM who gave birth between January 2017 and January 2019 at an obstetrics and gynecology hospital in Sofia, Bulgaria. Patients were assigned to three groups, according to the treatment approach — metformin group (n = 70), insulin group (n = 40), and MNT group (n = 123). Values of fasting plasma glucose (FPG) and glycated hemoglobin (HbA1c) have been evaluated at diagnosis of GDM and the third trimester of pregnancy. A comparative analysis of pregnancy outcomes and short-term neonatal characteristics in the investigated groups has been performed.

Results: Women indicated for pharmacological treatment (metformin or insulin) had significantly higher BMI (p < 0.01), FPG (p < 0.001), and HbA1c levels (p < 0.001) at baseline. However, during pregnancy, patients treated with metformin showed a significantly lower BMI (p < 0.01), FPG (p < 0.01), and HbA1c (p < 0.01). Neonates born to metformin-treated mothers had lower birth weight compared to those born to women in the MNT and insulin groups (metformin vs MNT, p < 0.001; metformin vs insulin, p = 0.03). The lowest incidence of newborns with macrosomia and neonatal hypoglycemia has been observed in the metformin cohort. Not a single newborn with an Apgar score under 7 has been identified in the metformin group.

Conclusions: According to the current analysis, women with GDM treated with metformin demonstrated better maternal and neonatal outcomes. No short-term complications in newborns have been associated with metformin use during pregnancy.

Article available in PDF format

View PDF Download PDF file


  1. Hod M, Kapur A, Sacks DA, et al. The International Federation of Gynecology and Obstetrics (FIGO) Initiative on gestational diabetes mellitus: A pragmatic guide for diagnosis, management, and care. Int J Gynaecol Obstet. 2015; 131 Suppl 3: S173–S211.
  2. International Diabetes Federation. IDF Diabetes Atlas, 10th edn. International Diabetes Federation, Brussels, Belgium 2021.
  3. Jiwani A, Marseille E, Lohse N, et al. Gestational diabetes mellitus: results from a survey of country prevalence and practices. J Matern Fetal Neonatal Med. 2012; 25(6): 600–610.
  4. Kim C, Newton KM, Knopp RH. Gestational diabetes and the incidence of type 2 diabetes: a systematic review. Diabetes Care. 2002; 25(10): 1862–1868.
  5. Vounzoulaki E, Khunti K, Abner SC, et al. Progression to type 2 diabetes in women with a known history of gestational diabetes: systematic review and meta-analysis. BMJ. 2020; 369: m1361.
  6. Kim C, Berger DK, Chamany S. Recurrence of gestational diabetes mellitus: a systematic review. Diabetes Care. 2007; 30(5): 1314–1319.
  7. Tam WH, Ma RC, Ozaki R, et al. In Utero Exposure to Maternal Hyperglycemia Increases Childhood Cardiometabolic Risk in Offspring. Diabetes Care. 2017; 40(5): 679–686.
  8. Poolsup N, Suksomboon N, Amin M. Effect of treatment of gestational diabetes mellitus: a systematic review and meta-analysis. PLoS One. 2014; 9(3): e92485.
  9. American Diabetes Association. 14. Management of Diabetes in Pregnancy: . Diabetes Care. 2021; 44(Suppl 1): S200–S210.
  10. National Institute for Health and Care Excellence. Diabetes in pregnancy: management from preconception to the postnatal period. London: National Institute for Health and Care Excellence; 2015. https://www.nice.org.uk/guidance/ng3/resources/diabetes-in-pregnancy-management-from-preconception-to-the-postnatal-period-51038446021.
  11. Society of Maternal-Fetal Medicine (SMFM) Publications Committee. Electronic address: pubs@smfm.org. SMFM Statement: Pharmacological treatment of gestational diabetes. Am J Obstet Gynecol. 2018; 218(5): B2–B4.
  12. Feig DS, Berger H, Donovan L, et al. Diabetes Canada Clinical Practice Guidelines Expert Committee. Diabetes and Pregnancy. Can J Diabetes. 2018; 42 Suppl 1: S255–S282.
  13. Schäfer-Graf UM, Gembruch U, Kainer F, et al. Gestational Diabetes Mellitus (GDM) - Diagnosis, Treatment and Follow-Up. Guideline of the DDG and DGGG (S3 Level, AWMF Registry Number 057/008, February 2018). Geburtshilfe Frauenheilkd. 2018; 78(12): 1219–1231.
  14. Caughey AB, Turrentine MA. PRACTICE BULLETIN: Gestational Diabetes Mellitus. Obstetrics and gynecology. 2018; 131(2): E49–E64.
  15. Harrison RK, Cruz M, Wong A, et al. The timing of initiation of pharmacotherapy for women with gestational diabetes mellitus. BMC Pregnancy Childbirth. 2020; 20(1): 773.
  16. Staynova R, Getova V. Georguiev St. Gestational Diabetes Mellitus – a Review of Current Pharmacological Strategies and Alternative Treatment Methods. Science Pharmacology. 2018; 2: 13–20.
  17. Kalra B, Gupta Y, Singla R, et al. Use of oral anti-diabetic agents in pregnancy: a pragmatic approach. N Am J Med Sci. 2015; 7(1): 6–12.
  18. Baker C, Retzik-Stahr C, Singh V, et al. Should metformin remain the first-line therapy for treatment of type 2 diabetes? Ther Adv Endocrinol Metab. 2021; 12: 2042018820980225.
  19. Sivadasan, S, Subramanian, M., Aiyalu, R. Metformin: Pros and Cons. In: Akhtar, J., Ahmad, U., Badruddeen, B., Khan, M. I., editors. Metformin - Pharmacology and Drug Interactions [Internet]. London: IntechOpen; 2021. https://www.intechopen.com/chapters/78326 (7.03.2022).
  20. Singh AK, Singh R. Metformin in gestational diabetes: An emerging contender. Indian J Endocrinol Metab. 2015; 19(2): 236–244.
  21. Blumer I, Hadar E, Hadden DR, et al. Diabetes and pregnancy: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2013; 98(11): 4227–4249.
  22. Metzger BE, Gabbe SG, Persson B, et al. International Association of Diabetes and Pregnancy Study Groups Consensus Panel. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care. 2010; 33(3): 676–682.
  23. Liao MZ, Flood Nichols SK, Ahmed M, et al. Effects of Pregnancy on the Pharmacokinetics of Metformin. Drug Metab Dispos. 2020; 48(4): 264–271.
  24. Farrar D, Simmonds M, Bryant M, et al. Treatments for gestational diabetes: a systematic review and meta-analysis. BMJ Open. 2017; 7(6): e015557.
  25. Cassina M, Donà M, Di Gianantonio E, et al. First-trimester exposure to metformin and risk of birth defects: a systematic review and meta-analysis. Hum Reprod Update. 2014; 20(5): 656–669.
  26. Gilbert C, Valois M, Koren G. Pregnancy outcome after first-trimester exposure to metformin: a meta-analysis. Fertil Steril. 2006; 86(3): 658–663.
  27. Hellmuth E, Damm P, Mølsted-Pedersen L. Oral hypoglycaemic agents in 118 diabetic pregnancies. Diabet Med. 2000; 17(7): 507–511.
  28. Rowan JA, Hague WM, Gao W, et al. MiG Trial Investigators. Metformin versus insulin for the treatment of gestational diabetes. N Engl J Med. 2008; 358(19): 2003–2015.
  29. McGrath RT, Glastras SJ, Scott ES, et al. Outcomes for Women with Gestational Diabetes Treated with Metformin: A Retrospective, Case-Control Study. J Clin Med. 2018; 7(3).
  30. Tertti K, Ekblad U, Vahlberg T, et al. Comparison of metformin and insulin in the treatment of gestational diabetes: a retrospective, case-control study. Rev Diabet Stud. 2008; 5(2): 95–101.
  31. Goh JEL, Sadler L, Rowan J. Metformin for gestational diabetes in routine clinical practice. Diabet Med. 2011; 28(9): 1082–1087.